Jun 12, 2023 / 12:00PM GMT
Operator
Good morning, and welcome to the Intellia Therapeutics NTLA-2002 Interim Clinical Data Update Event. My name is Drew, and I will be your conference operator today. Following formal remarks, we will open the call up for a question-and-answer session. This conference is being recorded at the company's request and will be available on the company's website following the end of the call. (Operator Instructions)
I will now turn the conference over to Ian Karp, Senior Vice President of Investor Relations and Corporate Communications at Intellia. Please proceed.
Ian Karp - Intellia Therapeutics, Inc. - SVP of IR & Corporate Communications
Thank you, operator, and good morning, everyone. I'm pleased to welcome you to Intellia's investor call, featuring updated interim data from the Phase I portion of the ongoing NTLA-2002 Phase I/II study. On Sunday, Intellia issued a press release detailing these results, which are presented at the European Academy of Allergy and Clinical Immunology Hybrid Congress held this past week in Hamburg, Germany and virtually.
Intellia Therapeutics Inc To Discuss Interim Clinical Data from Ongoing First-in-Human Study of NTLA-2002 for the Treatment of Hereditary Angioedema Transcript
Already have an account? Log in
Get the full story
Access to All Earning Calls and Stock Analysis | |
30-Year Financial on one screen | |
All-in-one Stock Screener with unlimited filters | |
Customizable Stock Dashboard | |
Real Time Insider Trading Transactions | |
8,000+ Institutional investors’ 13F holdings | |
Powerful Excel Add-in and Google sheets Add-on | |
All data downloadable | |
Quick customer support | |
And much more... |
30-Day 100% money back guarantee
You are not charged until the trial ends. Subscription fee may be tax deductible.
Excellent
4.6 out of 5 Trustpilot